Availability, quality and relevance of toxicogenomics data for human health risk assessment: A scoping review of the literature on trihalomethanes.


  • Date de publication : 2018-03-05

Référence

Vachon J, Pagé-Larivière F, Sirard MA, Rodriguez MJ, Levallois P, Campagna C. Availability, quality and relevance of toxicogenomics data for human health risk assessment: A scoping review of the literature on trihalomethanes. Toxicol Sci. 2018 Mar 5. doi: 10.1093/toxsci/kfy050. [Epub ahead of print] PubMed PMID: 29514332.

Résumé

 Human health risk assessment (HHRA) must be adapted to the challenges of the 21st century, and the use of toxicogenomics data in HHRA is among the changes that regulatory agencies worldwide are trying to implement. However, the use of toxicogenomics data in HHRA is still limited. The purpose of this study was to explore the availability, quality and relevance to HHRA of toxicogenomics publications as potential barriers to their use in HHRA. We conducted a scoping review of available toxicogenomics literature, using trihalomethanes as a case study. Four bibliographic databases (including the Comparative Toxicogenomics Database) were assessed. An evaluation table was developed to characterise quality and relevance of studies included on the basis of criteria proposed in the literature. Studies were selected and analysed by two independent reviewers. Only nine studies, published between 1997 and 2015, were included in the analysis. Based on the selected criteria, critical methodological details were often missing; in fact, only three out of nine studies were considered to be of adequate quality for HHRA. No studies met more than three (out of seven) criteria of relevance to HHRA (e.g. adequate number of doses and sample size, etc.). This first scoping review of toxicogenomics publications on trihalomethanes shows that low availability, quality and relevance to HHRA of toxicogenomics publications presents potential barriers to their use in HHRA. Improved reporting of methodological details and study design is needed in the future so that toxicogenomics studies can be appropriately assessed regarding their quality and value for HHRA.  


Retour